Competing Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity

Background and Objectives: Adenoid cystic carcinoma of the breast is a rare special-type tumor that is characteristically triple-negative yet behaves indolently, unlike conventional triple-negative disease. How its mortality is divided between the cancer itself and competing causes, and how that balance changes with age, has not been characterized in a contemporary population-based cohort. Materials and Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER-17, 2000–2023), we identified women with primary breast adenoid cystic carcinoma (ICD-O-3 8200/3). After restriction to first or only malignant primaries and exclusion of metastatic disease, 917 patients were analyzed. Breast cancer-specific survival (BCSS) and overall survival were estimated by Kaplan–Meier; competing-risk cumulative incidence (breast cancer vs. other-cause death) was estimated by the Aalen–Johansen estimator, overall and by age, with differences across age groups tested. Determinants of breast cancer death were modeled with cause-specific Cox regression restricted to patients with known grade. Results: The median age was 62 years; of the whole cohort, 81.4% of tumors were localized and 3.5% were node-positive, and 75.6% of classifiable cases were triple-negative. BCSS was 95.9%, 93.3%, and 91.2% at 5, 10, and 15 years. Although 205 women (22.4%) died, only 53 (5.8%) died of breast cancer; the 15-year cumulative incidence of non-cancer death (24.0%) was threefold that of breast cancer death (8.1%) and approximated the expected background mortality for this age. Breast cancer death did not differ across age groups, whereas other-cause death rose steeply with age: at 10 years, it reached 39% versus 7% for cancer in women aged ≥ 70, in whom only 13% of all deaths were cancer-related. Among patients with known grade, node positivity (hazard ratio 8.40) and high grade (2.42) predicted breast cancer death, whereas age did not. The competing-mortality structure was unchanged in the documented triple-negative subset. Conclusions: Breast adenoid cystic carcinoma is a predominantly triple-negative but indolent malignancy in which competing, non-cancer mortality dominates the clinical course, overwhelmingly so in older women, and breast cancer death is largely confined to high-grade, node-positive tumors. These findings favor individualized, age-adapted management rather than routine escalation based on the triple-negative label alone.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-18
DOI
https://doi.org/10.3390/medicina62112266
Primary Topic
Breast Lesions and Carcinomas
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Competing Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity

İsmail Zihni, Demet Sarıdemir Ünal, Mehmet Zafer Sabuncuoğlu, İmren Mutlu
Medicina
Breast Lesions and Carcinomas
article

Competing Mortality and Prognostic Structure in Adenoid Cystic Carcinoma of the Breast: A Population-Based Competing-Risk Analysis of a Predominantly Triple-Negative but Indolent Entity

İsmail Zihni, Demet Sarıdemir Ünal, Mehmet Zafer Sabuncuoğlu, İmren Mutlu
article en

Abstract

Background and Objectives: Adenoid cystic carcinoma of the breast is a rare special-type tumor that is characteristically triple-negative yet behaves indolently, unlike conventional triple-negative disease. How its mortality is divided between the cancer itself and competing causes, and how that balance changes with age, has not been characterized in a contemporary population-based cohort. Materials and Methods: Using the Surveillance, Epidemiology, and End Results Program (SEER-17, 2000–2023), we identified women with primary breast adenoid cystic carcinoma (ICD-O-3 8200/3). After restriction to first or only malignant primaries and exclusion of metastatic disease, 917 patients were analyzed. Breast cancer-specific survival (BCSS) and overall survival were estimated by Kaplan–Meier; competing-risk cumulative incidence (breast cancer vs. other-cause death) was estimated by the Aalen–Johansen estimator, overall and by age, with differences across age groups tested. Determinants of breast cancer death were modeled with cause-specific Cox regression restricted to patients with known grade. Results: The median age was 62 years; of the whole cohort, 81.4% of tumors were localized and 3.5% were node-positive, and 75.6% of classifiable cases were triple-negative. BCSS was 95.9%, 93.3%, and 91.2% at 5, 10, and 15 years. Although 205 women (22.4%) died, only 53 (5.8%) died of breast cancer; the 15-year cumulative incidence of non-cancer death (24.0%) was threefold that of breast cancer death (8.1%) and approximated the expected background mortality for this age. Breast cancer death did not differ across age groups, whereas other-cause death rose steeply with age: at 10 years, it reached 39% versus 7% for cancer in women aged ≥ 70, in whom only 13% of all deaths were cancer-related. Among patients with known grade, node positivity (hazard ratio 8.40) and high grade (2.42) predicted breast cancer death, whereas age did not. The competing-mortality structure was unchanged in the documented triple-negative subset. Conclusions: Breast adenoid cystic carcinoma is a predominantly triple-negative but indolent malignancy in which competing, non-cancer mortality dominates the clinical course, overwhelmingly so in older women, and breast cancer death is largely confined to high-grade, node-positive tumors. These findings favor individualized, age-adapted management rather than routine escalation based on the triple-negative label alone.

MedicinaVol. 62(11)
Akdeniz University (TR)
Good health and well-being
Breast Lesions and Carcinomas
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon